Elicio Therapeutics Inc (ELTX) Actualités

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of...

Form 8-K - Current report

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting

Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced...

Form 8-K - Current report

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral...

Form 8-K - Current report

Elicio Therapeutics Reports Inducement Grants

BOSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements